Credit Suisse’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.86M | Buy |
54,671
+27
| +0% | +$804 | ﹤0.01% | 1902 |
|
|
2023
Q4 | $1.58M | Buy |
54,644
+3,952
| +8% | +$105K | ﹤0.01% | 2036 |
|
|
2023
Q3 | $1.4M | Sell |
50,692
-2,906
| -5% | -$88.5K | ﹤0.01% | 2059 |
|
|
2023
Q2 | $1.61M | Buy |
53,598
+7,411
| +16% | +$259K | ﹤0.01% | 2074 |
|
|
2023
Q1 | $1.67M | Buy |
46,187
+362
| +0.8% | +$13.9K | ﹤0.01% | 1991 |
|
|
2022
Q4 | $1.63M | Buy |
45,825
+520
| +1% | +$18.1K | ﹤0.01% | 1998 |
|
|
2022
Q3 | $1.53M | Buy |
45,305
+251
| +0.6% | +$8.17K | ﹤0.01% | 2030 |
|
|
2022
Q2 | $1.3M | Sell |
45,054
-10,140
| -18% | -$290K | ﹤0.01% | 2197 |
|
|
2022
Q1 | $1.78M | Buy |
55,194
+2,610
| +5% | +$80K | ﹤0.01% | 2163 |
|
|
2021
Q4 | $1.53M | Buy |
52,584
+644
| +1% | +$19.5K | ﹤0.01% | 2989 |
|
|
2021
Q3 | $1.38M | Sell |
51,940
-5,581
| -10% | -$150K | ﹤0.01% | 3097 |
|
|
2021
Q2 | $1.77M | Buy |
57,521
+4,151
| +8% | +$127K | ﹤0.01% | 2960 |
|
|
2021
Q1 | $1.4M | Sell |
53,370
-99,224
| -65% | -$2.78M | ﹤0.01% | 3071 |
|
|
2020
Q4 | $3.84M | Sell |
152,594
-19,394
| -11% | -$417K | ﹤0.01% | 2313 |
|
|
2020
Q3 | $3.58M | Sell |
171,988
-14,984
| -8% | -$340K | ﹤0.01% | 2006 |
|
|
2020
Q2 | $4.44M | Buy |
186,972
+19,197
| +11% | +$424K | ﹤0.01% | 1776 |
|
|
2020
Q1 | $3.02M | Buy |
167,775
+105,238
| +168% | +$2.21M | ﹤0.01% | 1845 |
|
|
2019
Q4 | $1.48M | Buy |
62,537
+12,162
| +24% | +$295K | ﹤0.01% | 2848 |
|
|
2019
Q3 | $1.39M | Buy |
50,375
+19,389
| +63% | +$574K | ﹤0.01% | 2763 |
|
|
2019
Q2 | $1.02M | Sell |
30,986
-14,579
| -32% | -$500K | ﹤0.01% | 2916 |
|
|
2019
Q1 | $1.6M | Sell |
45,565
-17,394
| -28% | -$647K | ﹤0.01% | 2543 |
|
|
2018
Q4 | $2.09M | Sell |
62,959
-7,317
| -10% | -$315K | ﹤0.01% | 2211 |
|
|
2018
Q3 | $3.54M | Sell |
70,276
-10,705
| -13% | -$529K | ﹤0.01% | 1929 |
|
|
2018
Q2 | $4.85M | Sell |
80,981
-2,817
| -3% | -$146K | ﹤0.01% | 1757 |
|
|
2018
Q1 | $3.84M | Buy |
83,798
+22,349
| +36% | +$933K | ﹤0.01% | 1896 |
|
|
2017
Q4 | $2.45M | Sell |
61,449
-11,270
| -15% | -$445K | ﹤0.01% | 2278 |
|
|
2017
Q3 | $2.91M | Buy |
72,719
+15,847
| +28% | +$686K | ﹤0.01% | 2226 |
|
|
2017
Q2 | $2.45M | Sell |
56,872
-20,780
| -27% | -$740K | ﹤0.01% | 2101 |
|
|
2017
Q1 | $2.43M | Sell |
77,652
-986
| -1% | -$26.4K | ﹤0.01% | 2205 |
|
|
2016
Q4 | $1.99M | Sell |
78,638
-12,752
| -14% | -$285K | ﹤0.01% | 2447 |
|
|
2016
Q3 | $2.26M | Buy |
91,390
+1,239
| +1% | +$28K | ﹤0.01% | 2286 |
|
|
2016
Q2 | $1.83M | Buy |
90,151
+65,068
| +259% | +$1.15M | ﹤0.01% | 2395 |
|
|
2016
Q1 | $383K | Sell |
25,083
-24,021
| -49% | -$313K | ﹤0.01% | 3384 |
|
|
2015
Q4 | $660K | Buy |
49,104
+14,988
| +44% | +$232K | ﹤0.01% | 3162 |
|
|
2015
Q3 | $479K | Sell |
34,116
-78,133
| -70% | -$1.45M | ﹤0.01% | 3425 |
|
|
2015
Q2 | $1.91M | Buy |
112,249
+16,131
| +17% | +$230K | ﹤0.01% | 2594 |
|
|
2015
Q1 | $1.16M | Sell |
96,118
-65,037
| -40% | -$615K | ﹤0.01% | 2851 |
|
|
2014
Q4 | $1.34M | Buy |
161,155
+77,528
| +93% | +$651K | ﹤0.01% | 2891 |
|
|
2014
Q3 | $726K | Buy |
83,627
+64,692
| +342% | +$584K | ﹤0.01% | 3339 |
|
|
2014
Q2 | $207K | Sell |
18,935
-65,792
| -78% | -$586K | ﹤0.01% | 4333 |
|
|
2014
Q1 | $757K | Sell |
84,727
-5,581
| -6% | -$51.4K | ﹤0.01% | 3366 |
|
|
2013
Q4 | $681K | Sell |
90,308
-9,000
| -9% | -$62.9K | ﹤0.01% | 3563 |
|
|
2013
Q3 | $728K | Buy |
+99,308
| New | +$667K | ﹤0.01% | 3214 |
|
Other funds holding SUPN
AC
PCH
SIMG
GKIM
Credit Suisse's SUPN Position: Q1 2024 in Review
Credit Suisse increased its Supernus Pharmaceuticals (SUPN) stake by 0.05% in Q1 2024, buying an estimated $804 and bringing the position to 54,671 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1902.
Credit Suisse first reported a position in SUPN in Q3 2013 and has held it in 43 quarters since. The position peaked at $4.85M in Q2 2018. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.
- Credit Suisse held 54,671 shares of Supernus Pharmaceuticals worth $1.86M as of Q1 2024.
- Credit Suisse bought 27 Supernus Pharmaceuticals shares in Q1 2024, an estimated $804.
- Supernus Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1902 holding.
- Credit Suisse first reported a position in Supernus Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- Credit Suisse's Supernus Pharmaceuticals position peaked at $4.85M in Q2 2018.
- 250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.